Marta Casarrubios

5PUBLICATIONS
64CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 08, 2025
Pancreatic cancer-restricted cryptic antigens are targets for T cell recognition.

Zackery A Ely, Zachary J Kulstad, Gurcan Gunaydin

|Sep 28, 2022
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.

Marta Casarrubios, Mariano Provencio, Ernest Nadal

|May 16, 2022
Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial).

Mariano Provencio, Roberto Serna-Blasco, Ernest Nadal

|Aug 11, 2021
Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy.

Marta Casarrubios, Alberto Cruz-Bermúdez, Ernest Nadal

|Jul 29, 2021
Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.

Raquel Laza-Briviesca, Alberto Cruz-Bermúdez, Ernest Nadal

Pageof 1

Frequent Collaborators

4 joint publications

Alberto Cruz-Bermúdez

4 joint publications

Ernest Nadal

4 joint publications

Amelia Insa

4 joint publications

Atocha Romero